text_1: 此外 , 在 PD - L1 表达 水平 < 1% 的 患者 中 , 纳武利 尤 单抗 + 伊匹 单抗 组 患者 的 总 生存期 和 缓解 持续时间 ( 差异 接近 10 个 月 ) 均 超过 纳武利 尤 单抗 + 化疗 组 , 但 统计学 分级 检验 未 包含 此项 分析 .
  
text_2: in addition , among the patients with a PD @-@ L1 expression level of less than 1 % , those who received nivolumab plus ipilimumab had longer overall survival and a longer duration of response ( a difference of nearly 10 months ) than did those who received nivolumab plus chemotherapy , although this analysis was not part of the statistical testing hierarchy .
  